Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Alkermes, Inc. clinical trials
The registry lists 92 studies whose lead sponsor is Alkermes, Inc. or one of 2 companies grouped under it. 8 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 9, 2026.
Keep track of what changes. Save the Alkermes, Inc. studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesRegistry sponsor names on this page
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Alkermes, Inc..
- Alkermes, Inc.82 studiesSame company
Something wrong?
- 6 studies →
- 4 studies →
Focus areas
Conditions Alkermes, Inc. leads ten or more studies in, by study count. A broader condition is left out when almost all its studies are already in a narrower one listed here.
Studies
Recruiting first, then most recently updated. Showing 50 of 92. Browse all 92 →
- A Long-Term Study of ALKS 2680 in Subjects With Narcolepsy and Idiopathic HypersomniaRecruitingNCT06767683Phase 2/3
- A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 2RecruitingNCT07502443Phase 3
- A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1RecruitingNCT07455383Phase 3
- A Study to Evaluate the Efficacy, Safety and Tolerability of ALKS 2680 in Adults With Narcolepsy Type 1 (Brilliance NT1 - 304)RecruitingNCT07540897Phase 3
- A Study to Evaluate Safety and Efficacy of ALKS 7290 Compared With Placebo in Adult Participants With Attention Deficit Hyperactivity Disorder (ALKS 7290-201)RecruitingNCT07755410Phase 2
- Long-term Safety Extension Study of OLZ/SAM in Pediatric SubjectsEnrolling by invitationNCT04987229Phase 3
- Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I DisorderRecruitingNCT05303064Phase 3
- An Expanded Access Program (EAP) for OLZ/SAM in Pediatric Participants With Schizophrenia or Bipolar I Disorder (ALKS 3831-315)AvailableNCT07744113
- A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Idiopathic HypersomniaActive, not recruitingNCT06843590Phase 2
- A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Narcolepsy Type 1 (ALKS 2680-201)CompletedNCT06358950Phase 2
- Safety and Efficacy of FT218 in Idiopathic Hypersomnia (REVITALYZ)CompletedNCT06525077Phase 3
Sponsor listed in the registry: Avadel · First submitted before Avadel became part of Alkermes, Inc.
- A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Narcolepsy Type 2CompletedNCT06555783Phase 2
- Observational Study of LUMRYZ in NarcolepsyCompletedNCT06792708
Sponsor listed in the registry: Avadel · First submitted before Avadel became part of Alkermes, Inc.
- An Open Label Study of FT218 in Subjects With NarcolepsyCompletedNCT04451668Phase 3
Sponsor listed in the registry: Avadel · First submitted before Avadel became part of Alkermes, Inc.
- Phase 3 Study of Nemvaleukin Alfa in Combination With Pembrolizumab in Patients With Platinum-Resistant Epithelial Ovarian Cancer (ARTISTRY-7)TerminatedNCT05092360Phase 3
Sponsor listed in the registry: Mural Oncology, Inc · First submitted before Mural Oncology, Inc left Alkermes, Inc.
- Nemvaleukin Alfa Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Cutaneous or Mucosal Melanoma - ARTISTRY-6TerminatedNCT04830124Phase 2
Sponsor listed in the registry: Mural Oncology, Inc · First submitted before Mural Oncology, Inc left Alkermes, Inc.
- A Study of the Effects of ALKS 4230 (Nemvaleukin Alfa) on Subjects With Solid TumorsCompletedNCT02799095Phase 1/2
Sponsor listed in the registry: Mural Oncology, Inc · First submitted before Mural Oncology, Inc left Alkermes, Inc.
- A Study of ALKS 4230 (Nemvaleukin Alfa) With Pembrolizumab in Head and Neck CancerCompletedNCT04144517Phase 2
Sponsor listed in the registry: Mural Oncology, Inc · First submitted before Mural Oncology, Inc left Alkermes, Inc.
- Study to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831CompletedNCT03201757Phase 3
- Less Frequent IV Dosing & Tumor Microenvironment (TME) Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy and in Combination With Pembrolizumab (ARTISTRY-3)Active, not recruitingNCT04592653Phase 1/2
Sponsor listed in the registry: Mural Oncology, Inc · First submitted before Mural Oncology, Inc left Alkermes, Inc.
- A Dose Escalation and Cohort Expansion Study of Subcutaneously-Administered Cytokine ALKS 4230 (Nemvaleukin Alfa) as a Single Agent and in Combination With Anti-PD-1 Antibody (Pembrolizumab) in Subjects With Select Advanced or Metastatic Solid Tumors (ARTISTRY-2)CompletedNCT03861793Phase 1/2
Sponsor listed in the registry: Mural Oncology, Inc · First submitted before Mural Oncology, Inc left Alkermes, Inc.
- Phase 1 Study of OLZ/SAM in Pediatric Subjects With Bipolar I DisorderCompletedNCT04987658Phase 1
- Study of the Breast Milk Pharmacokinetics of Olanzapine and SamidorphanCompletedNCT05547100Phase 1
- Observational Study of Long Acting Injectable Medications (LAIs) in Schizophrenia (OASIS)CompletedNCT03919994
- Study to Evaluate the Efficacy of ALKS 3831 on Body Weight in Young Adults Who Have Been Recently Diagnosed With Schizophrenia, Schizophreniform, or Bipolar I DisorderCompletedNCT03187769Phase 3
- Phase 1 ALKS 1140 in Healthy AdultsTerminatedNCT05019105Phase 1
- Once-Nightly Sodium Oxybate for Treatment of Excessive Daytime Sleepiness and Cataplexy in NarcolepsyCompletedNCT02720744Phase 3
Sponsor listed in the registry: Avadel · First submitted before Avadel became part of Alkermes, Inc.
- A Study of ALKS 3831 in Subjects With Schizophrenia and Alcohol Use DisorderCompletedNCT02161718Phase 2
- A Study of ALKS 3831 in Adults With SchizophreniaCompletedNCT01903837Phase 2
- A Phase 3, Long-term Safety and Tolerability Study of ALKS 3831 in Adults With SchizophreniaCompletedNCT02873208Phase 3
- A Long Term Study of ALKS 5461 in the Treatment of Refractory Major Depressive Disorder (MDD)TerminatedNCT03610048Phase 3
- A Study of ALKS 5461 for Treatment Refractory Major Depressive Disorder (MDD)CompletedNCT03188185Phase 3
- A Study of Aripiprazole Lauroxil or Paliperidone Palmitate for the Treatment of SchizophreniaCompletedNCT03345979Phase 3
- A 28 Day Parallel Group Study to Assess the Effects of RDN-929TerminatedNCT03963973Phase 1
- A Non-therapeutic Feasibility Study of the Radioligand [11C]-UCB-J for Imaging Synaptic DensityCompletedNCT03577262Early Phase 1
- Single and Multiple Ascending Dose and Food Effect PK Study in Healthy Adult and Elderly SubjectsCompletedNCT03668314Phase 1
- A Study of ALKS 3831 in Adults With Schizophrenia (The ENLIGHTEN-2 Study)CompletedNCT02694328Phase 3
- A Study of Different Titration Schedules of ALKS 5461 in Adults With Major Depressive Disorder (MDD)CompletedNCT02085135Phase 3
- A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - FORWARD-5 StudyCompletedNCT02218008Phase 3
- A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-4 StudyCompletedNCT02158533Phase 3
- A Long-Term Safety and Tolerability Study of ALKS 3831 in Adults With SchizophreniaCompletedNCT02669758Phase 3
- A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-3 StudyCompletedNCT02158546Phase 3
- A Study to Evaluate ALKS 5461 in Subjects With Major Depressive Disorder (MDD)CompletedNCT01500200Phase 2
- Naltrexone for Use in Conjunction With Buprenorphine in Adults With Opioid Use Disorder Prior to First Dose of VIVITROL® (Naltrexone for Extended-Release Injectable Suspension)CompletedNCT02537574Phase 3
- Evaluating Naltrexone for Use in Conjunction With Buprenorphine in Adults With Opioid Use Disorder Transitioning From Buprenorphine Maintenance Prior to First Dose of VIVITROLCompletedNCT02696434Phase 3
- A Study to Evaluate the Efficacy and Safety of ALKS 9072 (Also Known as Aripiprazole Lauroxil, ALKS 9070, or ARISTADA) in Subjects With SchizophreniaCompletedNCT01469039Phase 3
- A Long-Term Safety Study of ALKS 5461CompletedNCT02141399Phase 3
- ALK21-021: A Safety Study of Medisorb® Naltrexone (VIVITROL®) Administered to Health Care ProfessionalsCompletedNCT00834080Phase 3
- A Study of Aripiprazole Lauroxil (Also Known as ARISTADA TM) in Subjects With SchizophreniaCompletedNCT02634320Phase 4
- ALK21-025: Vivitrol's Cost and Treatment Outcomes RegistryCompletedNCT01422837